The HDL Conundrum: What’s Bad about Drugs for Good Cholesterol?

The stock of drug-maker Abbott Laboratories tanked May 26 after results were published on a trial of whether the B vitamin niacin can help prevent heart disease and strokes. The immediate follow-on question is whether the premise on which that trial was based, the so-called HDL Hypothesis, has just received another coffin nail

More:
The HDL Conundrum: What’s Bad about Drugs for Good Cholesterol?